Non-invasive Methods for Characterizing Adrenocortical Tumors


Adrenocortical neoplasms are commonly found in patients, yet malignant tumors resulting in adrenocortical cancer (ACC) are rare. An accurate diagnosis of ACC is important to a). determine the proper therapeutic strategy for patients, and b). mitigate the costs and risks of invasive surgeries. Improved pre-operative diagnostics would preclude unnecessary surgical intervention on benign adrenocortical neoplasms and lead to appropriate treatment options for malignant adrenocortical cancer (ACC).

Researchers at the NCI Endocrine Oncology Branch developed a non-invasive method to detect (ACC) in urine. They identified four metabolite markers in patient urine samples and have shown that these are sensitive and specific to malignant adrenocortical tumors: creatine riboside, L-tryptophan, N,N,N-trimethyl-L-lysine, and 3-methylhistidine. This method differentiates benign and malignant tumors, and helps clinicians decide the best treatment options.



Potential Commercial Applications: Competitive Advantages:
  • Urine-based diagnostic platforms to identify malignant adrenocortical tumors using biomarkers
 
  • First non-invasive diagnosis of adrenocortical cancer using urine samples
  • Differentiation between malignant and benign adrenocortical tumors without surgical intervention


Development Stage:
Pre-clinical (in vivo)

Related Invention(s):




Inventors:

Dhaval Patel (NCI)  ➽ more inventions...

Kristopher Krausz (NCI)  ➽ more inventions...

Frank Gonzalez (NCI)  ➽ more inventions...

Electron Kebebew (NCI)  ➽ more inventions...

Matthew Thompson (NCI)  ➽ more inventions...


Intellectual Property:
US Provisional Application No. 62/186,218
Foreign Filed Application No. PCT/US2016/040148

Publications:
Patel D et al. PMID 28450405

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-193-2015
Updated: Mar 21, 2018